바이오테크 보도자료
-
- Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody l...
- 02월 20일 10:10
-
- Yokogawa Provides Remote Operation/Monitoring System and Video Monitoring Solution for Japan’s Largest Wind Farm
- Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary Yokogawa Solution Service Corporation has completed the design, supply, and commissioning of a remote operation and monitoring system based on the OpreX™ Collaborative Infor...
- 02월 19일 13:55
-
- CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
- Correction by Galderma: Results from the OLYMPIA program demonstrated that more than half of nemolizumab-treated patients achieved an at least four-point reduction in itch intensity, as measured by the peak-pruritus numerical rating scale (PP-NRS;...
- 02월 14일 16:24
-
- Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
- Takeda (TSE:4502/NYSE:TAK ) today announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1...
- 02월 11일 11:15
-
- LambdaTest and QualityKiosk Technologies Partner to Elevate Enterprise Quality Assurance
- LambdaTest , a renowned cloud-based unified testing platform, and QualityKiosk Technologies, a globally recognized quality engineering services provider, proudly announce a strategic partnership. The partnership is designed to deliver tailored sol...
- 02월 08일 15:30
-
- Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
- Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder ...
- 02월 08일 14:00
-
- JT Group Recognized on CDP’s Climate Change A List and Water Security A List
- Japan Tobacco Inc. (JT) (TSE: 2914) has been recognized for its leadership in corporate sustainability by the global environmental non-profit organization CDP[1], for a fifth year in a row. The JT Group is one of 61 companies worldwide and 22 in J...
- 02월 07일 17:11
-
- Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows
- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plus with built-in Parse Evercode™ single cell pro...
- 02월 07일 11:15
-
- TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
- TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming...
- 02월 05일 17:40
-
- Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
- Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention...
- 02월 05일 14:40
-
- Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
- We are excited to share our latest development status. As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor re...
- 02월 04일 11:00
전시회
